Evidence map›Paper›PMID 28330952›Full record

ArticlePhysiological reports2017

Effects of insulin and the glucagon-like peptide 1 receptor agonist liraglutide on the kidney proteome in db/db mice.

Leena Liljedahl, Jenny Norlin, James N McGuire, Peter James

Open access · goldFull text read
In one paragraph

Article in Physiological reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Leena LiljedahlDepartment of Immunotechnology, Lund University, Lund, Sweden leena.liljedahl@immun.lth.se.
Jenny NorlinNovo Nordisk A/S, Måløv, Denmark.
James N McGuireNovo Nordisk A/S, Måløv, Denmark.
Peter JamesDepartment of Immunotechnology, Lund University, Lund, Sweden.
Lund University · SENovo Nordisk (Denmark) · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus (DM) is a worldwide disease that affects 9% of the adult world population and type 2 DM accounts for 90% of those. A common consequence of DM is kidney complications, which could lead to kidney failure. We studied the potential effects of treatment with insulin and the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide on the diabetic kidney proteome through the use of the db/db mouse model system and mass spectrometry (MS). Multivariate analyses revealed distinct effects of insulin and liraglutide on the db/db kidney proteome, which was seen on the protein levels of, for example, pterin-4

Indexed as

AnimalsDiabetes Mellitus, Type 2ElonginHepcidinsHydro-LyasesHypoglycemic AgentsInsulinKidneyLiraglutideMaleMiceNEDD8 ProteinObesityProteomeEloc protein, mouseElonginHepcidinsHydro-LyasesHypoglycemic AgentsInsulinLiraglutideNEDD8 ProteinNedd8 protein, mouseProteomepterin-4a-carbinolamine dehydrataseGLP‐1R agonist liraglutideinsulinkidney proteomeOPLS‐DA

Identifiers

PMID28330952
PMCPMC5371560
OpenAlexW2602070646

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.